XMT-1592

XMT-1592 is an ADC created using our proprietary Dolasynthen platform – a customizable and homogenous platform designed to precisely optimize an ADC for a given target, drug-to-antibody ratio (DAR) and antibody. XMT-1592 comprises the same proprietary NaPi2b antibody and potent auristatin DolaLock payload with controlled bystander effect as XMT-1536, with the additional features of site-specific bioconjugation, precise DAR and homogenous DAR distribution.  In preclinical studies, Dolasynthen ADCs show enhanced pharmacokinetics, higher tumor exposure, and greater efficacy compared to Dolaflexin ADCs. We plan to file an IND and initiate a Phase 1 dose escalation trial of XMT-1592 in patients with tumors likely to express NaPi2b in the first half of 2020.

XMT-1592